Patents by Inventor David J. Hinrichs
David J. Hinrichs has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10023538Abstract: Compounds, compositions and methods useful for treating infectious diseases are provided. In particular, 3-aryl quinoline compounds, their synthesis, pharmaceutical compositions thereof and methods of treating infectious diseases such as malaria, are disclosed.Type: GrantFiled: February 23, 2017Date of Patent: July 17, 2018Assignees: The United States of America as represented by the Department of Veterans Affairs, Oregon Health and Science UniversityInventors: Michael K. Riscoe, Rolf W. Winter, Sovitj Pou, David J. Hinrichs, Jane Xu Kelly, Yuexin Li, Aaron Nilsen
-
Publication number: 20180009760Abstract: Compounds, compositions and methods useful for treating infectious diseases are provided. In particular, 3-aryl quinoline compounds, their synthesis, pharmaceutical compositions thereof and methods of treating infectious diseases such as malaria, are disclosed.Type: ApplicationFiled: February 23, 2017Publication date: January 11, 2018Applicants: Oregon Health & Science University, The United States Government as Represented by the Department of Veterans AffairsInventors: Michael K. Riscoe, Rolf W. Winter, Sovitj Pou, David J. Hinrichs, Jane Xu Kelly, Yuexin Li, Aaron Nilsen
-
Publication number: 20170144974Abstract: A class of acridone compounds has been discovered that exhibits chemosensitizing and antiparasitic activity. Described herein are pharmaceutical compositions and methods for their use to treat parasitic infections, such as malaria and toxoplasmosis, and to sensitize resistant cells, such as multidrug resistant cells to other therapeutic agents. The pharmaceutical compositions and methods may also be used to treat and/or prevent psychotic diseases such as schizophrenia.Type: ApplicationFiled: June 22, 2016Publication date: May 25, 2017Applicants: Oregon Health & Science University, Government of the United states of America dba The Department of Veterans AffairsInventors: Michael K. Riscoe, Rolf W. Winter, Jane X. Kelly, David J. Hinrichs, Martin J. Smilkstein
-
Publication number: 20160340313Abstract: Compounds, compositions and methods useful for treating infectious diseases are provided. In particular, 3-aryl quinoline compounds, their synthesis, pharmaceutical compositions thereof and methods of treating infectious diseases such as malaria, are disclosed.Type: ApplicationFiled: December 21, 2015Publication date: November 24, 2016Applicants: Oregon Health & Science University, The United States Government as Represented by the Department of Veterans AffairsInventors: Michael K. Riscoe, Rolf W. Winter, Sovitj Pou, David J. Hinrichs, Jane Xu Kelly, Yuexin Li, Aaron Nilsen
-
Patent number: 9399625Abstract: (A1) A class of acridone compounds has been discovered that exhibits chemosensitizing and antiparasitic activity. Described herein are pharmaceutical compositions and methods for their use to treat parasitic infections, such as malaria and toxoplasmosis, and to sensitize resistant cells, such as multidrug resistant cells to other therapeutic agents. The pharmaceutical compositions and methods may also be used to treat and/or prevent psychotic diseases such as schizophrenia.Type: GrantFiled: February 16, 2015Date of Patent: July 26, 2016Assignees: Oregon Health & Science University, The United States of AmericaInventors: Michael K. Riscoe, Rolf W. Winter, Jane X. Kelly, David J. Hinrichs, Martin J. Smilkstein
-
Patent number: 9249103Abstract: Compounds, compositions and methods useful for treating infectious diseases are provided. In particular, 3-aryl quinoline compounds, their synthesis, pharmaceutical compositions thereof and methods of treating infectious diseases such as malaria, are disclosed.Type: GrantFiled: January 14, 2013Date of Patent: February 2, 2016Assignees: Oregon Health & Science University, The United States of America as Represented by the Department of Veterans AffairsInventors: Michael K. Riscoe, Rolf W. Winter, Sovitj Pou, David J. Hinrichs, Jane Xu Kelly, Yuexin Li, Aaron Nilsen
-
Patent number: 9206131Abstract: Compounds of formula I: or formula II: or a pharmaceutically acceptable salt of formula I or formula II, wherein: R1 is H, hydroxyl, alkoxy, acyl, alkyl, cycloalkyl, aryl, or heteroaryl; R2 is methyl or haloalkyl; R4 is hydroxyl, carbonyloxy, or carbonyldioxy; and R3 is aliphatic, aryl, aralkyl, or alkylaryl; and R5, R6, R7 and R8 are each individually H, halogen, alkoxy, alkyl, haloalkyl, aryl, nitro, cyano, amino, amido, acyl, carboxyl, substituted carboxyl, or —SO2R10, wherein R10 is H, alkyl, amino or haloalkyl; provided that in formula I, R5 and R7 are not both H or R6 is not H or methoxy; and in formula II that if R4 is carbonyldioxy then R7 is not methoxy.Type: GrantFiled: October 16, 2013Date of Patent: December 8, 2015Assignees: Oregon Health & Science University, The Department of Veterans Affairs, Medicines for Malaria Venture, University of South FloridaInventors: Michael K. Riscoe, Jane X. Kelly, Rolf W. Winter, David J. Hinrichs, Martin J. Smilkstein, Aaron Nilsen, Jeremy Burrows, Dennis Kyle, Roman Manetsch, Richard M. Cross, Andrii Monastyrskyi, David L. Flanigan
-
Publication number: 20150210645Abstract: (A1) A class of acridone compounds has been discovered that exhibits chemosensitizing and antiparasitic activity. Described herein are pharmaceutical compositions and methods for their use to treat parasitic infections, such as malaria and toxoplasmosis, and to sensitize resistant cells, such as multidrug resistant cells to other therapeutic agents. The pharmaceutical compositions and methods may also be used to treat and/or prevent psychotic diseases such as schizophrenia.Type: ApplicationFiled: February 16, 2015Publication date: July 30, 2015Inventors: Michael K. Riscoe, Rolf W. Winter, Jane X. Kelly, David J. Hinrichs, Martin J. Smilkstein
-
Patent number: 8987296Abstract: A class of acridone compounds has been discovered that exhibits chemosensitizing and antiparasitic activity. Described herein are pharmaceutical compositions and methods for their use to treat parasitic infections, such as malaria and toxoplasmosis, and to sensitize resistant cells, such as multidrug resistant cells to other therapeutic agents. The pharmaceutical compositions and methods may also be used to treat and/or prevent psychotic diseases such as schizophrenia.Type: GrantFiled: October 29, 2013Date of Patent: March 24, 2015Assignees: Oregon Health & Science University, The United States of America DBA The Department of Veterans AffairsInventors: Michael K. Riscoe, Rolf W. Winter, Jane X. Kelly, David J. Hinrichs, Martin J. Smilkstein
-
Publication number: 20140350048Abstract: Compounds, compositions and methods useful for treating infectious diseases are provided. In particular, 3-aryl quinoline compounds, their synthesis, pharmaceutical compositions thereof and methods of treating infectious diseases such as malaria, are disclosed.Type: ApplicationFiled: January 14, 2013Publication date: November 27, 2014Inventors: Michael K. Riscoe, Rolf W. Winter, Sovitj Pou, David J. Hinrichs, Jane Xu Kelly, Yuexin Li, Aaron Nilsen
-
Publication number: 20140128423Abstract: A class of acridone compounds has been discovered that exhibits chemosensitizing and antiparasitic activity. Described herein are pharmaceutical compositions and methods for their use to treat parasitic infections, such as malaria and toxoplasmosis, and to sensitize resistant cells, such as multidrug resistant cells to other therapeutic agents. The pharmaceutical compositions and methods may also be used to treat and/or prevent psychotic diseases such as schizophrenia.Type: ApplicationFiled: October 29, 2013Publication date: May 8, 2014Applicants: Government of the United States of America dba The Department of Veterans Affairs, Oregon Health & Science UniversityInventors: Michael K. Riscoe, Rolf W. Winter, Jane X. Kelly, David J. Hinrichs, Martin J. Smilkstein
-
Publication number: 20140045888Abstract: Compounds of formula I: or formula II: or a pharmaceutically acceptable salt of formula I or formula II, wherein: R1 is H, hydroxyl, alkoxy, acyl, alkyl, cycloalkyl, aryl, or heteroaryl; R2 is methyl or haloalkyl; R4 is hydroxyl, carbonyloxy, or carbonyldioxy; and R3 is aliphatic, aryl, aralkyl, or alkylaryl; and R5, R6, R7 and R8 are each individually H, halogen, alkoxy, alkyl, haloalkyl, aryl, nitro, cyano, amino, amido, acyl, carboxyl, substituted carboxyl, or —SO2R10, wherein R10 is H, alkyl, amino or haloalkyl; provided that in formula I, R5 and R7 are not both H or R6 is not H or methoxy; and in formula II that if R4 is carbonyldioxy then R7 is not methoxy.Type: ApplicationFiled: October 16, 2013Publication date: February 13, 2014Applicants: Oregon Health & Science University, Medicines for Malaria Venture, University of South Florida, The Government of the United States of America dba The Department of Veterans AffairsInventors: Michael K. Riscoe, Jane X. Kelly, Rolf W. Winter, David J. Hinrichs, Martin J. Smilkstein, Aaron Nilsen, Jeremy Burrows, Dennis Kyle, Roman Manetsch, Richard M. Cross, Andrii Monastyrskyi, David L. Flanigan
-
Patent number: 8598354Abstract: Compounds of formula I: or formula II: or a pharmaceutically acceptable salt of formula I or formula II, wherein: R1 is H, hydroxyl, alkoxy, acyl, alkyl, cycloalkyl, aryl, or heteroaryl; R2 is methyl or haloalkyl; R4 is hydroxyl, carbonyloxy, or carbonyldioxy; and R3 is aliphatic, aryl, aralkyl, or alkylaryl; and R5, R6, R7 and R8 are each individually H, halogen, alkoxy, alkyl, haloalkyl, aryl, nitro, cyano, amino, amido, acyl, carboxyl, substituted carboxyl, or —SO2R10, wherein R10 is H, alkyl, amino or haloalkyl; provided that in formula I, R5 and R7 are not both H or R6 is not H or methoxy; and in formula II that if R4 is carbonyldioxy then R7 is not methoxy.Type: GrantFiled: June 3, 2011Date of Patent: December 3, 2013Assignees: University of South Florida, Medicines for Malaria VentureInventors: Michael K. Riscoe, Jane X. Kelly, Rolf W. Winter, David J. Hinrichs, Martin J. Smilkstein, Aaron Nilsen, Jeremy Burrows, Dennis Kyle, Roman Manetsch, Richard M. Cross, Andrii Monastyrskyi, David L. Flanigan
-
Patent number: 8592447Abstract: A class of acridone compounds has been discovered that exhibits chemosensitizing and antiparasitic activity. Described herein are pharmaceutical compositions and methods for their use to treat parasitic infections, such as malaria and toxoplasmosis, and to sensitize resistant cells, such as multidrug resistant cells to other therapeutic agents. The pharmaceutical compositions and methods may also be used to treat and/or prevent psychotic diseases such as schizophrenia.Type: GrantFiled: November 13, 2007Date of Patent: November 26, 2013Assignees: Oregon Health & Science University, The United States of America, as represented by the Department of Veterans AffairsInventors: Michael K. Riscoe, Rolf Winter, Jane X. Kelly, David J. Hinrichs, Martin J. Smilkstein
-
Patent number: 8481543Abstract: A compound, particularly an antimalarial compound, according to formula I: or a pharmaceutically acceptable salt thereof, wherein: X is an electron-withdrawing group; A is an optionally substituted alkanediyl or an optionally substituted cycloalkanediyl that includes 2 to 5 carbon atoms; and R1 and R2 are each individually H, tert-butyl, isopropyl, or optionally substituted cycloalkyl.Type: GrantFiled: November 17, 2009Date of Patent: July 9, 2013Assignees: Oregon Health & Science University, The United States of America as represented by the Department of Veterans AffairsInventors: Michael K. Riscoe, Rolf W. Winter, David J. Hinrichs
-
Publication number: 20120115904Abstract: Compounds of formula I: or formula II: or a pharmaceutically acceptable salt of formula I or formula II, wherein: R1 is H, hydroxyl, alkoxy, acyl, alkyl, cycloalkyl, aryl, or heteroaryl; R2 is methyl or haloalkyl; R4 is hydroxyl, carbonyloxy, or carbonyldioxy; and R3 is aliphatic, aryl, aralkyl, or alkylaryl; and R5, R6, R7 and R8 are each individually H, halogen, alkoxy, alkyl, haloalkyl, aryl, nitro, cyano, amino, amido, acyl, carboxyl, substituted carboxyl, or —SO2R10, wherein R10 is H, alkyl, amino or haloalkyl; provided that in formula I, R5 and R are not both H or R6 is not H or methoxy; and in formula II that if R4 is carbonyldioxy then R7 is not methoxy.Type: ApplicationFiled: June 3, 2011Publication date: May 10, 2012Inventors: Michael K. Riscoe, Jane X. Kelly, Rolf W. Winter, David J. Hinrichs, Martin J. Smilkstein, Aaron Nilsen, Jeremy Burrows, Dennis Kyle, Roman Manetsch, Richard M. Cross, Andrii Monastyrskyi, David L. Flanigan
-
Publication number: 20120027791Abstract: A method and conjugate for selectively killing antigen-activated T cells are disclosed. The conjugate is composed of a substantially uncharged antisense compound targeted against the human cFLIP protein, and a reverse TAT (rTAT) polypeptide coupled covalently to the antisense compound. The rTAT polypeptide is effective to produce selective uptake of the conjugate into antigen-activated T cells, relative to the uptake of the conjugate into non-activated T cells. The cFLIP antisense compound causes activation induced cell death (AICD) of activated lymphocytes. The method is useful in treating transplantation rejection and autoimmune conditions.Type: ApplicationFiled: July 20, 2011Publication date: February 2, 2012Applicant: AVI BIOPHARMA, INC.Inventors: Dan V. Mourich, Hong Mu Moulton, David J. Hinrichs, Patrick L. Iversen
-
Publication number: 20120010237Abstract: A method for inhibiting a parasitic or infectious disease in a subject, wherein the parasitic or infectious disease is selected from one caused by Eimeria sp., Babesia sp., Theileria sp. or Neospora caninum, the method comprising administering to the subject a therapeutically effective amount of a compound of formula I: or formula II: or a pharmaceutically acceptable salt of formula I or formula II, wherein: R1 is H, hydroxyl, alkoxy, acyl, alkyl, cycloalkyl, aryl, or heteroaryl; R2 is methyl, haloalkyl, or heteroaryl; R4 is hydroxyl, carbonyloxy, or carbonyldioxy; R3 is aliphatic, aryl, aralkyl, or alkylaryl; and R5, R6, R7 and R8 are each individually H, halogen, alkoxy, alkyl, haloalkyl, aryl, nitro, cyano, amino, amido, acyl, carboxyl, substituted carboxyl, or —SO2R10, wherein R10 is H, alkyl, amino or haloalkyl; provided that in formula I, R5 and R7 are not H or R6 is not H or methoxy; and in formula II that if R4 is carbonyldioxy then R7 is not methoxy.Type: ApplicationFiled: June 3, 2011Publication date: January 12, 2012Inventors: Michael K. Riscoe, Jane X. Kelly, Rolf W. Winter, David J. Hinrichs, Martin J. Smilkstein, Aaron Nilsen
-
Publication number: 20110251209Abstract: A compound, particularly an antimalarial compound, according to formula I: or a pharmaceutically acceptable salt thereof, wherein: X is an electron-withdrawing group; A is an optionally substituted alkanediyl or an optionally substituted cycloalkanediyl that includes 2 to 5 carbon atoms; and R1 and R2 are each individually H, tert-butyl, isopropyl, or optionally substituted cycloalkyl.Type: ApplicationFiled: November 17, 2009Publication date: October 13, 2011Inventors: Michael K. Riscoe, Rolf W. Winter, David J. Hinrichs
-
Patent number: 8008469Abstract: A method and conjugate for selectively killing antigen-activated T cells are disclosed. The conjugate is composed of a substantially uncharged antisense compound targeted against the human cFLIP protein, and a reverse TAT (rTAT) polypeptide coupled covalently to the antisense compound. The rTAT polypeptide is effective to produce selective uptake of the conjugate into antigen-activated T cells, relative to the uptake of the conjugate into non-activated T cells. The cFLIP antisense compound causes activation induced cell death (AICD) of activated lymphocytes. The method is useful in treating transplantation rejection and autoimmune conditions.Type: GrantFiled: November 15, 2007Date of Patent: August 30, 2011Assignee: AVI BioPharma Inc.Inventors: Dan V. Mourich, Hong M. Moulton, David J. Hinrichs, Patrick L. Iversen